Drug Trial Radar · NCT07943221
Study Evaluating Safety & Tolerability of Migaldendranib in US Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 12, 2026
Primary completion
Oct 23, 2026
Study completion Nov 20, 2026
Sponsor
- Lead sponsor
- Ashvattha Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB after weekly subQ MGB administration in up to 24 healthy volunteers at 1 site in the United States.
Conditions
- Healthy Volunteers
Interventions
Weekly subcutaneous administration of Migaldendranib (MGB)Drug
Participants receive weekly subcutaneous administration of MGB
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: Varying timepoints through end of treatment, up to approximately 29 days per cohort.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.